Drug intelligence / Profile preview

RENUBI 365 Autophagy

Development stage: Unknown
Lead developer: PICO Entech
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

RENUBI 365 Autophagy is a health supplement developed by PICO Entech, formulated as a combination of protein powder and ALDH (Aldehyde Dehydrogenase) dried yeast. It is marketed as an autophagy-mimicking or fasting-mimicking product designed to support cellular renewal and provide anti-aging benefits. The product leverages ALDH activity to potentially mitigate oxidative stress and support metabolic health, although it is classified as a nutraceutical rather than a pharmaceutical agent.

Brand names: RENUBI 365 AutophagyRENUBI365 AutophagyRENUBI-365 Autophagy
Other names: 리뉴비 365 오토파직RENUBI 365 AutophagicRENUBI365 AutophagicRENUBI-365 Autophagic

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)

Beyond the preview

Go deeper on RENUBI 365 Autophagy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RENUBI 365 Autophagy.

Explore the full profile